{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:01:53Z","timestamp":1791950513925,"version":"4.3.4"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.intimp.2016.11.005","type":"journal-article","created":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T22:16:09Z","timestamp":1479161769000},"page":"11-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The possible role of interleukin-35 and its therapeutic potential in pemphigus"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6765-8830","authenticated-orcid":false,"given":"Soheil","family":"Tavakolpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forough","family":"Kheiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajar Sadat","family":"Mirsafaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meisam","family":"Akhlaghdoust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2016.11.005_bb0005","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1067\/mjd.2002.116338","article-title":"Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy","volume":"46","author":"Ahmed","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0010","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1046\/j.1365-2230.2003.01283.x","article-title":"Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab)","volume":"28","author":"Cooper","year":"2003","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0015","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cyto.2015.09.017","article-title":"Interleukin 4 inhibition as a potential therapeutic in pemphigus","volume":"77","author":"Tavakolpour","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2016.11.005_bb0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.jid.5700059","article-title":"Inhibition of pemphigus vulgaris by targeting of the CD40\u2013CD154 co-stimulatory pathway: a step toward antigen-specific therapy?","volume":"126","author":"Liu","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0030","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.intimp.2016.04.031","article-title":"The dual nature of retinoic acid in pemphigus and its therapeutic potential: special focus on all-trans retinoic acid","volume":"36","author":"Tavakolpour","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0035","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12016-015-8468-9","article-title":"IL-35 and autoimmunity: a comprehensive perspective","volume":"49","author":"Choi","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1155\/2008\/875394","article-title":"Serum concentration of interleukin-6 is increased both in active and remission stages of pemphigus vulgaris","volume":"2008","author":"Narbutt","year":"2008","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.intimp.2016.11.005_bb0045","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1365-2133.2012.11144.x","article-title":"Enrichment of total serum IgG4 in patients with pemphigus","volume":"167","author":"Funakoshi","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0050","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000099585","article-title":"CD4+ CD25high regulatory T cells are markedly decreased in blood of patients with pemphigus vulgaris","volume":"214","author":"Sugiyama","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.intimp.2016.11.005_bb0055","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1684\/ejd.2013.2177","article-title":"The imbalance of Th17 and regulatory T cells in pemphigus patients","volume":"23","author":"Xu","year":"2013","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/bjd.13192","article-title":"Impaired function of CD19+ CD24hiCD38hi regulatory B cells in patients with pemphigus","volume":"172","author":"Zhu","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0065","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2230.2005.01836.x","article-title":"Direct characterization of human T cells in pemphigus vulgaris reveals elevated autoantigen-specific Th2 activity in association with active disease","volume":"30","author":"Rizzo","year":"2005","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0070","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1080\/08820130902943097","article-title":"Involvement of TH1\/TH2 cytokines in the pathogenesis of autoimmune skin disease\u2014pemphigus vulgaris","volume":"38","author":"Satyam","year":"2009","journal-title":"Immunol. Investig."},{"key":"10.1016\/j.intimp.2016.11.005_bb0075","doi-asserted-by":"crossref","first-page":"635","DOI":"10.4049\/jimmunol.170.1.635","article-title":"Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles","volume":"170","author":"Veldman","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0080","first-page":"175","article-title":"IL-17 and Th17 cells in rheumatoid arthritis. Th 17 cells: role in inflammation and autoimmune disease","author":"Miossec","year":"2009","journal-title":"Springer"},{"key":"10.1016\/j.intimp.2016.11.005_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-3083.2011.02536.x","article-title":"Th17 cell, the new player of neuroinflammatory process in multiple sclerosis","volume":"74","author":"Jadidi-Niaragh","year":"2011","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2014.05.004","article-title":"Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus","volume":"154","author":"Martin","year":"2014","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jdermsci.2008.09.008","article-title":"Lesional Th17 cells in pemphigus vulgaris and pemphigus foliaceus","volume":"53","author":"Arakawa","year":"2009","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.intimp.2016.11.005_bb0100","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1371\/journal.pone.0035572","article-title":"Inflammation-driven reprogramming of CD4 Foxp3 regulatory T cells into pathogenic Th1\/Th17 T effectors is abrogated by mTOR inhibition in vivo","volume":"7","author":"Yurchenko","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2016.11.005_bb0105","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nm.3432","article-title":"Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis","volume":"20","author":"Komatsu","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2016.11.005_bb0110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1155\/2015\/137893","article-title":"Vitamin A impairs the reprogramming of tregs into IL-17-producing cells during intestinal inflammation","volume":"2015","author":"Tejon","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.intimp.2016.11.005_bb0115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/1346-8138.12697","article-title":"Immune cellular regulation on autoantibody production in pemphigus","volume":"42","author":"Pan","year":"2015","journal-title":"J. Dermatol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0120","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/cmi.2012.60","article-title":"Regulatory B cells in autoimmune diseases","volume":"10","author":"Yang","year":"2013","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0125","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.4049\/jimmunol.181.2.1526","article-title":"Novel system evaluating in vivo pathogenicity of desmoglein 3-reactive T cell clones using murine pemphigus vulgaris","volume":"181","author":"Takahashi","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1172\/JCI119130","article-title":"Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris","volume":"99","author":"Lin","year":"1997","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.intimp.2016.11.005_bb0135","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00403-014-1522-2","article-title":"Study of T helper 1 and T helper 2 responses in pemphigus vulgaris patients receiving interferon alpha 2a injections in addition to a standard protocol therapy: a randomized controlled trial","volume":"307","author":"El-Darouti","year":"2015","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.intimp.2016.11.005_bb0140","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/dth.12327","article-title":"Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus","volume":"29","author":"Tavakolpour","year":"2016","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.intimp.2016.11.005_bb0145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.intimp.2016.02.020","article-title":"Interleukin 21 as a new possible player in pemphigus: is it a suitable target?","volume":"34","author":"Tavakolpour","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0150","series-title":"IL-6 Promotes the Differentiation of a Subset of Naive CD8+ T Cells into IL-21-Producing B Helper CD8+ T Cells","first-page":"2281","volume":"213","author":"Yang","year":"2016"},{"key":"10.1016\/j.intimp.2016.11.005_bb0155","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.immuni.2012.05.027","article-title":"STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease","volume":"37","author":"Laurence","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2016.11.005_bb0160","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.0105-2896.2006.00420.x","article-title":"Interleukin-10-secreting type 1 regulatory T cells in rodents and humans","volume":"212","author":"Grazia Roncarolo","year":"2006","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2016.11.005_bb0165","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.4049\/jimmunol.160.7.3555","article-title":"IgE versus IgG4 production can be differentially regulated by IL-10","volume":"160","author":"Jeannin","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0170","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2016.11.005_bb0175","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ni1497","article-title":"Development, cytokine profile and function of human interleukin 17\u2013producing helper T cells","volume":"8","author":"Wilson","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0180","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2249.2007.03356.x","article-title":"The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease","volume":"148","author":"Afzali","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0185","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature05970","article-title":"IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells","volume":"448","author":"Korn","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2016.11.005_bb0190","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature07021","article-title":"IL-21 and TGF-&bgr; are required for differentiation of human TH17 cells","volume":"454","author":"Yang","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2016.11.005_bb0195","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2016.11.005_bb0200","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1155\/2014\/463928","article-title":"Overexpression of interleukin-23 and interleukin-17 in the lesion of pemphigus vulgaris: a preliminary study","volume":"2014","author":"Xue","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.intimp.2016.11.005_bb0205","first-page":"174","article-title":"The effect of conventional immunosuppressive therapy on cytokine serum levels in pemphigus vulgaris patients","volume":"13","author":"Mortazavi","year":"2014","journal-title":"Iranian Journal of Allergy, Asthma and Immunology"},{"key":"10.1016\/j.intimp.2016.11.005_bb0210","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2016.11.005_bb0215","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/intimm\/dxr020","article-title":"Antigen-independent development of Foxp3+ regulatory T cells suppressing autoantibody production in experimental pemphigus vulgaris","volume":"23","author":"Yokoyama","year":"2011","journal-title":"Int. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0220","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/39614","article-title":"A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis","volume":"389","author":"Groux","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2016.11.005_bb0225","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/cmi.2015.44","article-title":"Type 1 regulatory T cells: a new mechanism of peripheral immune tolerance","volume":"12","author":"Zeng","year":"2015","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0230","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.4049\/jimmunol.172.10.6468","article-title":"Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris","volume":"172","author":"Veldman","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0235","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.4049\/jimmunol.172.6.3883","article-title":"T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals","volume":"172","author":"Veldman","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0240","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.4049\/jimmunol.176.5.3215","article-title":"Inhibition of the transcription factor Foxp3 converts desmoglein 3-specific type 1 regulatory T cells into Th2-like cells","volume":"176","author":"Veldman","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0245","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1038\/jid.2008.172","article-title":"Rituximab exerts a dual effect in pemphigus vulgaris","volume":"128","author":"Eming","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0250","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/ni.1952","article-title":"Interleukin-35-mediated induction of a novel regulatory T cell population","volume":"11","author":"Collison","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0255","doi-asserted-by":"crossref","unstructured":"Shamji MH, Layhadi J, Perera-web A, Yan R, Durham SR. IL-35-producing T cells (iTR35) inhibit Th2 effector function, induce infectious tolerance and are elevated following grass pollen sublingual immunotherapy. J. Allergy Clin. Immunol.133:AB51.","DOI":"10.1016\/j.jaci.2013.12.206"},{"key":"10.1016\/j.intimp.2016.11.005_bb0260","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1155\/2014\/136329","article-title":"The possible role of the novel cytokines IL-35 and IL-37 in inflammatory bowel disease","volume":"2014","author":"Li","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.intimp.2016.11.005_bb0265","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.4049\/jimmunol.176.6.3498","article-title":"Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells","volume":"176","author":"Crawford","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0270","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.4049\/jimmunol.167.3.1575","article-title":"Impaired T cell immunity in B cell-deficient mice following viral central nervous system infection","volume":"167","author":"Bergmann","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0275","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev-immunol-020711-074934","article-title":"Immune regulatory function of B cells","volume":"30","author":"Mauri","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0280","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/intimm\/dxv038","article-title":"The expanding family of regulatory B cells","volume":"27","author":"Mauri","year":"2015","journal-title":"Int. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0285","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/intimm\/dxv033","article-title":"IL-10-independent regulatory B-cell subsets and mechanisms of action","volume":"27","author":"Ray","year":"2015","journal-title":"Int. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0290","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1172\/JCI8748","article-title":"Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus","volume":"105","author":"Amagai","year":"2000","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.intimp.2016.11.005_bb0295","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/jid.2008.178","article-title":"B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses","volume":"128","author":"Mouquet","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0300","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1038\/jid.2008.330","article-title":"Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion","volume":"128","author":"Zambruno","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0305","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005407","article-title":"CD19+ CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation","volume":"5","author":"Flores-Borja","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2016.11.005_bb0310","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.4049\/jimmunol.1001307","article-title":"Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis","volume":"185","author":"Matsushita","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0315","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2016.11.005_bb0320","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature12979","article-title":"IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases","volume":"507","author":"Shen","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2016.11.005_bb0325","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nm.3554","article-title":"Interleukin-35 induces regulatory B cells that suppress autoimmune disease","volume":"20","author":"Wang","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2016.11.005_bb0330","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jmcb\/mjr039","article-title":"Induced Foxp3(+) regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases?","volume":"4","author":"Lan","year":"2012","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0335","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cyto.2014.11.002","article-title":"The dual nature of interleukin-10 in pemphigus vulgaris","volume":"73","author":"Cho","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2016.11.005_bb0340","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4049\/jimmunol.1100259","article-title":"Airway inflammation and IgE production induced by dust mite allergen-specific memory\/effector Th2 cell line can be effectively attenuated by IL-35","volume":"187","author":"C-H","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0345","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.4049\/jimmunol.0902739","article-title":"IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10","volume":"184","author":"Kochetkova","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0350","doi-asserted-by":"crossref","first-page":"AB208","DOI":"10.1016\/j.jaci.2011.12.200","article-title":"Interleukin-35 suppresses allergen-specific Th2 response in patients with grass pollen induced seasonal allergic rhinitis","volume":"129","author":"Achkova","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0355","first-page":"379","article-title":"Decreased circulating interleukin-35 levels are related to interleukin-4-producing CD8+ T cells in patients with allergic asthma","volume":"14","author":"Wang","year":"2015","journal-title":"Iranian Journal of Allergy, Asthma and Immunology"},{"key":"10.1016\/j.intimp.2016.11.005_bb0360","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.imlet.2016.02.008","article-title":"The new insight into management of hepatitis B virus patients with flare","volume":"173","author":"Tavakolpour","year":"2016","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.intimp.2016.11.005_bb0365","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.35810","article-title":"Hepatitis B reactivation during immunosuppressive therapy or cancer chemotherapy, management, and prevention: a comprehensive review","volume":"16","author":"Tavakolpour","year":"2016","journal-title":"Hepat. Mon."},{"key":"10.1016\/j.intimp.2016.11.005_bb0370","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.imlet.2015.12.007","article-title":"Inhibition of regulatory cells as a possible cure of chronically hepatitis B virus infected patients","volume":"171","author":"Tavakolpour","year":"2016","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.intimp.2016.11.005_bb0375","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cyto.2014.06.020","article-title":"IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis: evidence for a role as an autocrine growth factor","volume":"70","author":"Nicholl","year":"2014","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2016.11.005_bb0380","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.4049\/jimmunol.1202535","article-title":"Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis","volume":"190","author":"Wang","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0385","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.7314\/APJCP.2015.16.7.2845","article-title":"IL-35 over-expression is associated with genesis of gastric cancer","volume":"16","author":"Fan","year":"2015","journal-title":"Asian Pacific journal of cancer prevention: APJCP"},{"key":"10.1016\/j.intimp.2016.11.005_bb0390","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archderm.1984.01650430127024","article-title":"Adjuvant therapy of pemphigus","volume":"120","author":"Bystryn","year":"1984","journal-title":"Arch. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2016.11.005_bb0395","first-page":"1173","article-title":"Anti-interleukin and associated receptors monoclonal antibodies therapy in autoimmune diseases","volume":"3","author":"Tavakolpour","year":"2016","journal-title":"Receptors & Clinical Investigation"},{"key":"10.1016\/j.intimp.2016.11.005_bb0400","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/sji.12428","article-title":"Blockage of T cell activation via anti-CD40 and anti-CD154 monoclonal antibodies can possibility treat alopecia areata","volume":"83","author":"Tavakolpour","year":"2016","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0405","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/sji.12423","article-title":"Janus kinase inhibitors against other biological treatments in alopecia areata","volume":"83","author":"Tavakolpour","year":"2016","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.intimp.2016.11.005_bb0410","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrd3683","article-title":"Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer","volume":"12","author":"von Boehmer","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2016.11.005_bb0415","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.coph.2009.04.008","article-title":"Anti-inflammatory and pro-inflammatory roles of TGF-\u03b2, IL-10, and IL-22 in immunity and autoimmunity","volume":"9","author":"Sanjabi","year":"2009","journal-title":"Curr. Opin. Pharmacol."}],"updated-by":[{"DOI":"10.1016\/j.intimp.2017.10.031","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000}}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576916304465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576916304465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T01:37:57Z","timestamp":1755740277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576916304465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":83,"alternative-id":["S1567576916304465"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2016.11.005","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.intimp.2017.10.031","asserted-by":"object"}]},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The possible role of interleukin-35 and its therapeutic potential in pemphigus","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2016.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}